By proceeding, you agree to our Terms of Use and Privacy Policy.
Jamil M. Beg joined 5AM Ventures in 2017 as a Principal. Prior to 5AM, Mr. Beg was at Sage Therapeutics (NASDAQ: SAGE). Prior to Sage, Mr.
Talks About #Healthcare
Preferred Locations #NorthAmerica
The 10th Neurodegenerative Disease Drug Development Summit will be discussing, debating and exploring pivotal neurodegenerative disease research from the past 12 months.